Tralokinumab    (DrugBank: Tralokinumab)

2 diseases
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia3
97Ulcerative colitis6

85. Idiopathic interstitial pneumonia    [ 514 clinical trials,   377 drugs,   (DrugBank: 108 drugs),   97 drug target genes,   204 drug target pathways]
Searched query = "Idiopathic interstitial pneumonia", "IIPs", "Idiopathic pulmonary fibrosis", "IPF", "Usual interstitial pneumonia", "UIP", "Non-specific interstitial pneumonia", "NSIP", "Acute interstitial pneumonia", "AIP", "Diffuse alveolar damage", "DAD", "COP", "Organizing pneumonia", "OP", "Desquamative interstitial pneumonia", "DIP", "Respiratory bronchiolitis - associated interstitial lung disease", "RB-ILD", "Lymphocytic interstitial pneumonia", "LIP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 514 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02036580
(ClinicalTrials.gov)
January 201413/1/2014D2212C00002 J-Phase II StudyA Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: tralokinumab cohort 1;Biological: tralokinumab cohort 2;Other: PlaceboAstraZenecaMedImmune LLCCompleted50 YearsN/AAll37Phase 2Japan
2NCT01629667
(ClinicalTrials.gov)
October 201212/6/2012A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary FibrosisA Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: Tralokinumab;Other: PlaceboMedImmune LLCNULLTerminated50 Years79 YearsAll409Phase 2United States;Australia;Canada;Israel;Korea, Republic of;Peru
3JPRN-JapicCTI-142452
21/02/2014A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary FibrosisA Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary FibrosisIntervention name : Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
Dosage And administration of the intervention : Low Dose, Biological: tralokinumab cohort 1, High Dose, Biological: tralokinumab cohort 2
AstraZenecaMedImmune LLC50BOTHPhase 2NULL

97. Ulcerative colitis    [ 2,269 clinical trials,   1,331 drugs,   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways]
Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
6 / 2,269 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004812-40-GB
(EUCTR)
12/04/201221/03/2012Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2Czech Republic;Netherlands;Germany;Italy;United Kingdom
2NCT01482884
(ClinicalTrials.gov)
March 201229/11/2011Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative ColitisA Phase IIa, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study to Evaluate the Efficacy and Safety of Tralokinumab (CAT-354), a Recombinant Human Monoclonal Antibody Directed Against Interleukin-13 (IL-13), as add-on Therapy, on Clinical Response in Patients With Active, Moderate-to-severe, Ulcerative ColitisUlcerative ColitisDrug: tralokinumab;Drug: placeboAstraZenecaMedImmune LtdCompleted18 Years65 YearsAll147Phase 2Czech Republic;France;Germany;Italy;Poland;United Kingdom;Netherlands
3EUCTR2011-004812-40-DE
(EUCTR)
26/01/201225/11/2011Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2aCzech Republic;Netherlands;Germany;United Kingdom;Italy
4EUCTR2011-004812-40-NL
(EUCTR)
25/01/201222/12/2011Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 15.0;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2aCzech Republic;Netherlands;United Kingdom;Italy
5EUCTR2011-004812-40-CZ
(EUCTR)
24/01/201229/12/2011Evaluation of efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
110Phase 2aCzech Republic;Netherlands;United Kingdom;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2011-004812-40-IT
(EUCTR)
12/12/201102/03/2012A phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitisA phase IIa, randomised, double-blind, placebo-controlled, parallel-arm, multicenter study to evaluate the efficacy and safety of tralokinumab (CAT-354), a recombinant human monoclonal antibody directed against interleukin-13 (IL-13), as add-on therapy, on clinical response in patients with active, moderate-to-severe, ulcerative colitis Ulcerative Colitis
MedDRA version: 14.1;Level: LLT;Classification code 10045282;Term: UC;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: tralokinumab
Product Code: CAT-354
INN or Proposed INN: tralokinumab
Other descriptive name: NA
ASTRAZENECANULLNot RecruitingFemale: yes
Male: yes
110Phase 2aCzech Republic;Netherlands;Germany;United Kingdom;Italy